Hansa Biopharma Q1: The European launch regains momentum - Redeye
Following low volumes in the previous Q4, Hansa’s Q1 is well above the rolling 12m average, and the product sales of SEK 65.7m are the highest recovered to date by far. The OPEX base is also well-contained in Q1.
ANNONS
Following low volumes in the previous Q4, Hansa’s Q1 is well above the rolling 12m average, and the product sales of SEK 65.7m are the highest recovered to date by far. The OPEX base is also well-contained in Q1.
